/ CORRECTION - Corcept Therapeutics
June 20 2014 - 4:14PM
Marketwired
/ CORRECTION - Corcept Therapeutics
CHICAGO, IL--(Marketwired - Jun 20, 2014) - In the news release,
"New Research on Corcept's Korlym(R) for Patients With Cushing's
Syndrome to Be Presented at ICE/ENDO 2014," issued Thursday, June
19, 2014 by Corcept Therapeutics (NASDAQ: CORT), we are advised by
the company that the session schedule has now been updated to
reflect accurate presentation times with poster numbers added.
Complete corrected text follows.
New Research on Corcept's Korlym® for Patients With Cushing's
Syndrome to Be Presented at ICE/ENDO 2014
New Data Includes Results of a Long-Term Extension Phase of
Corcept's Multicenter, Open-Label SEISMIC Study
CHICAGO, IL -- Jun 19, 2014 -- Corcept Therapeutics
Incorporated (NASDAQ: CORT), a pharmaceutical company engaged
in the discovery, development and commercialization of drugs for
the treatment of severe metabolic, psychiatric and oncologic
disorders, today announced that new clinical research on Korlym®
(mifepristone) will be presented at the joint meeting of the
International Society of Endocrinology and the Endocrine Society
(ICE/ENDO 2014).
The research, including results of a long-term extension phase
of Corcept's multicenter, open-label SEISMIC study of Korlym, will
be presented at the conference, taking place at the McCormick Place
West Convention Center in Chicago from June 21-24. Korlym is a
once-daily oral treatment for patients with Cushing's syndrome who
have glucose intolerance and have failed or cannot have
surgery.
"Cushing's syndrome, which is caused by excessive cortisol
activity, is a serious condition that has a debilitating impact on
all aspects of patients' lives. The disease often significantly
affects patients' metabolism, leading to extreme weight gain with
abnormal fat deposits, impaired glycemic control including type 2
diabetes, muscle weakness and, commonly, psychiatric symptoms,"
said Joseph K. Belanoff, M.D., Corcept's Chief Executive Officer.
"Because Cushing's syndrome may be a chronic disease, it is
important to monitor patients taking Korlym over time. The
long-term extension study of SEISMIC includes data from patients
who had been receiving treatment for as long as 3.5 years."
Cushing's syndrome is the result of excessive cortisol activity
throughout the body. Cortisol is a hormone made in the adrenal
glands that performs vital tasks such as regulating the metabolism
of proteins, carbohydrates and fats. Cushing's syndrome afflicts
20,000 people in the United States, with approximately 3,000 to
4,000 new cases each year. Approximately half of these patients are
cured by surgery.
The following abstracts highlight new research on
mifepristone:
|
|
|
|
|
|
Date |
Session Time |
Poster Number |
Title |
|
Authors |
Saturday, June 21, 2014 |
11:30am-1:00pm |
OR02-2 |
Late-Night Salivary Cortisol for the Diagnosis of Recurrent
Cushing's Disease: Evidence of Clinical Benefit from Early
Detection |
|
Ty Brian Carroll, MD; Bradley R Javorsky, MD; James W Findling,
MD |
1:00-3:00pm |
SAT-0671 |
Clinical Management in a Female with Persistent Cushing's Disease
Treated with Mifepristone for Four Years |
|
Elizabeth E King, MD; Simone M Howell, RN, CCRA |
Sunday, June 22, 2014 |
1:00-3:00pm |
SUN-0750 |
Effect of Mifepristone on Cushing's syndrome Secondary to Bilateral
Adrenal Adenomas: A Case Presentation |
|
Vijay Babu Balakrishnan; Pankaj Sharda, MBBS, MD; Elias Said Siraj,
MD |
Monday, June 23, 2014 |
1:00-3:00pm |
MON-0439 |
Improved Activities of Daily Living, Normal Mood and Quality of
Life: 4 Years of Treatment Data in a Premenopausal Woman with
Cushing's Disease |
|
Daphne T Adelman, BSN, MBA; Simone M Howell, RN, CCRA |
MON-0592 |
A Case Report of a 37 y/o Woman Diagnosed with Cushing's Disease
Presenting As Pituitary Apoplexy after Multiple Treatment Failures
Effectively Responds to Mifepristone |
|
Howard A Brand, MD; Kimberly Calcagno, MA; Michele Lamerson, RN,
MS, CPNP |
MON-0595 |
Discontinuation of Insulin, Oral Antidiabetic and Antihypertensive
Medications in a Patient with Cushing's Disease Following
Mifepristone (MIFE) Therapy |
|
Kevin C.J. Yuen, MD, FRCP (UK); Harold I Magazine, PhD |
MON-0598 |
Mifepristone for Refractory Cushing's Syndrome in a Patient with
CKD Hyperkalemia Undergoing Surgical Exodontia and Weight Loss:
Recommendations for Clinical/Biochemical Monitoring and
Perioperative Dosing |
|
Audrey Elisabeth Arzamendi, MD; Alison Marie Semrad, DO |
MON-0663 |
Persistent Weight Loss in Patients Treated with Mifepristone (MIFE)
for Cushing's Syndrome: Results from the Seismic & Long Term
Extension Studies |
|
Henry G. Fein, MD; T. Brooks Vaughan III, MD; Coleman Gross; Dat
Nguyen |
|
|
|
|
|
|
About Corcept Therapeutics Incorporated Corcept is a
pharmaceutical company engaged in the discovery, development and
commercialization of drugs that regulate the effects of the stress
hormone cortisol on the body. The FDA has approved the company's
first drug, Korlym® (mifepristone) 300 mg Tablets, a glucocorticoid
receptor antagonist, as a once-daily oral treatment for
hyperglycemia secondary to endogenous Cushing's syndrome in adult
patients with glucose intolerance or diabetes mellitus type 2 who
have failed surgery or are not candidates for surgery. Corcept is
exploring mifepristone (the active ingredient in Korlym) as a
treatment for triple-negative breast cancer with a multi-center,
Phase I clinical study currently underway in patients with
metastatic or locally advanced unresectable breast cancer. It is
also supporting investigator-led clinical studies of mifepristone
in the treatment of ovarian cancer and castration-resistant
prostate cancer. The company has a portfolio of selective
glucocorticoid-receptor (GR) antagonists that block the effects of
cortisol but not progesterone. It owns or has licensed extensive
intellectual property covering the use of GR antagonists, including
mifepristone, in the treatment of a wide variety of metabolic and
psychiatric disorders and triple-negative breast cancer. It also
holds composition of matter patents for its selective GR
antagonists.
Investor Contact Charles Robb Corcept Therapeutics Incorporated
Chief Financial Officer Email Contact 650-688-8783 Media Contact
Brian Baxter for Corcept Lazar Partners Ltd. Email Contact
646-871-8491
Corcept Therapeutics (NASDAQ:CORT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Corcept Therapeutics (NASDAQ:CORT)
Historical Stock Chart
From Apr 2023 to Apr 2024